Effects of Dipeptidyl Peptidase-4 Inhibitor Linagliptin on Left Ventricular Dysfunction in Patients with Type 2 Diabetes and Concentric Left Ventricular Geometry (the DYDA 2™ Trial). Rationale, Design, and Baseline Characteristics of the Study Population.

Abstract:

PURPOSE:A multicentre, randomized, double-blind, placebo-controlled, parallel-group study aimed to define the potential positive effect of dipeptidyl peptidase-4 inhibition on left ventricular systolic function (LVSF) beyond glycemic control in type 2 diabetes mellitus (T2DM) (DYDA 2™ trial). METHODS:Individuals with fairly controlled T2DM and asymptomatic impaired LVSF were randomized in a 1:1 ratio to receive for 48 weeks either linagliptin 5 mg daily or placebo, in addition to their stable diabetes therapy. Eligibility criteria were age ≥ 40 years, history of T2DM with a duration of at least 6 months, HbA1c ≤ 8.0% (≤ 64 mmol/mol), no history or clinical signs/symptoms of cardiac disease, evidence at baseline echocardiography of concentric LV geometry (relative wall thickness ≥ 0.42), and impaired LVSF defined as midwall fractional shortening (MFS) ≤ 15%. The primary end-point was the modification from baseline to 48 weeks of MFS. As an exploratory analysis, significant changes in LV global longitudinal strain and global circumferential strain, measured by speckle tracking echocardiography, were also considered. Secondary objectives were changes in diastolic and/or in systolic longitudinal function as measured by tissue Doppler. RESULTS:A total of 188 patients were enrolled. They were predominantly males, mildly obese, with typical insulin-resistance co-morbidities such as hypertension and dyslipidemia. Mean relative wall thickness was 0.51 ± 0.09 and mean MFS 13.3% ± 2.5. CONCLUSIONS:DYDA 2 is the first randomized, double-blind, placebo-controlled trial to explore the effect of a dipeptidyl peptidase-4 inhibitor on LVSF in T2DM patients in primary prevention regardless of glycemic control. The main characteristics of the enrolled population are reported. TRIAL REGISTRATION:ClinicalTrial.gov Identifier: NCT02851745.

journal_name

Cardiovasc Drugs Ther

authors

Giorda CB,Cioffi G,Lucci D,Nada E,Ognibeni F,Mancusi C,Latini R,Maggioni AP,DYDA 2 Investigators.

doi

10.1007/s10557-019-06898-6

subject

Has Abstract

pub_date

2019-10-01 00:00:00

pages

547-555

issue

5

eissn

0920-3206

issn

1573-7241

pii

10.1007/s10557-019-06898-6

journal_volume

33

pub_type

杂志文章
  • Combined treatment with ramipril and metoprolol prevents changes in the creatine kinase isoenzyme system and improves hemodynamic function in rat hearts after myocardial infarction.

    abstract::Beneficial effects of monotherapy with ACE inhibitors or beta-blockers on hemodynamic function after myocardial infarction are well known. Until now, the effects of combined treatment on cardiac function and energy metabolism have been poorly described. This study examines the effects of combined ramipril and metoprol...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1023/a:1007846311040

    authors: Theres HP,Wagner KD,Romberg D,Feig C,Strube S,Leiterer KP,Günther J,Stangl K,Baumann G,Schimke I

    更新日期:2000-12-01 00:00:00

  • Ranolazine Attenuates the Electrophysiological Effects of Myocardial Stretch in Langendorff-Perfused Rabbit Hearts.

    abstract:PURPOSE:Mechanical stretch is an arrhythmogenic factor found in situations of cardiac overload or dyssynchronic contraction. Ranolazine is an antianginal agent that inhibits the late Na (+) current and has been shown to exert a protective effect against arrhythmias. The present study aims to determine whether ranolazin...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-015-6587-4

    authors: Chorro FJ,del Canto I,Brines L,Such-Miquel L,Calvo C,Soler C,Parra G,Zarzoso M,Trapero I,Tormos Á,Alberola A,Such L

    更新日期:2015-06-01 00:00:00

  • Pharmacotherapy of dyslipidemia.

    abstract::Reducing elevated levels of low-density-lipoprotein cholesterol (LDL-C) significantly reduces the incidence of coronary heart disease (CHD) events and mortality in hypercholesterolemic patients. CHD risk reduction is proportional to LDL-C reduction. Despite this knowledge, many physicians are not applying existing tre...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1023/a:1013341606476

    authors: McKenney JM

    更新日期:2001-09-01 00:00:00

  • Methods of assessing the functional status of patients with left ventricular systolic dysfunction in interventional studies: can brain natriuretic peptide measurement be used as surrogate for the traditional methods?

    abstract:AIM:To review whether brain natriuretic peptides (BNP) can be used as a surrogate for the traditional methods of assessing functional status in interventional studies of patients with left ventricular systolic dysfunction (LVSD). METHODS AND RESULTS:The traditional methods for assessing functional status including New...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1023/B:CARD.0000033643.93393.46

    authors: Abdulla J,Køber L,Torp-Pedersen C

    更新日期:2004-05-01 00:00:00

  • Rationale for combining a direct renin inhibitor with other renin- angiotensin system blockers. Focus on aliskiren and combinations.

    abstract::Inhibition of the renin-angiotensin system has been a highly successful therapeutic approach for the prevention of hypertension-related end organ damage. Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers lower blood pressure and reduce morbidity and mortality in patients with cardiovascular...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1007/s10557-010-6278-0

    authors: Siragy HM

    更新日期:2011-02-01 00:00:00

  • Benefit of antihypertensive treatment in the diabetic patients enrolled in the Systolic Hypertension in Europe (Syst-Eur) trial.

    abstract::In this review we attempt to determine the role of calcium channel blockers in preventing cardiovascular sequelae in patients with both hypertension and diabetes mellitus. The data have been collected from three sources: post-hoc analyses of subgroups of diabetic patients in placebo-controlled hypertension trials (SHE...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1023/a:1007891121240

    authors: Gasowski J,Birkenhäger WH,Staessen JA,de Leeuw PW

    更新日期:2000-02-01 00:00:00

  • Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R). Rationale for the study and protocol design.

    abstract:PURPOSE:To assess whether glycoprotein IIb/IIIa inhibition using tirofiban in low risk patients undergoing percutaneous coronary intervention (PCI) may reduce the risk of periprocedural myocardial infarction compared to standard care in poor responders to aspirin and/or clopidogrel. METHODS:We will enroll patients at ...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s10557-008-6121-z

    authors: Valgimigli M,Campo G,de Cesare N,Vranckx P,Hamon M,Angiolillo DJ,Sabatè M,Ferrari F,Furgieri A,Tumscitz C,Repetto A,Colangelo S,Meliga E,Kubbajeh M,Parrinello G,Percoco G,Ferrari R

    更新日期:2008-08-01 00:00:00

  • Biodegradable polymer drug-eluting stents versus second-generation drug-eluting stents for patients with coronary artery disease: an update meta-analysis.

    abstract:OBJECTIVE:Permanent polymer drug-eluting stents (DES) are associated with a higher risk of late and very late stent thrombosis (ST); biodegradable polymer drug-eluting stents (BP-DES) were designed to reduce these risks. However, their benefits are not completely clear. METHOD:We undertook a meta-analysis of randomize...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,meta分析

    doi:10.1007/s10557-014-6528-7

    authors: Wang Y,Dong P,Li L,Li X,Wang H,Yang X,Wang S,Li Z,Shang X

    更新日期:2014-08-01 00:00:00

  • High-Density Lipoprotein Function and Dysfunction in Health and Disease.

    abstract::High-density lipoprotein cholesterol (HDL-c) has long been referred to as 'good cholesterol' due to its apparent inverse relationship with future CVD risk. More recent research has questioned a causal role for HDL-c in this relationship, however, as both genetic studies and numerous large-scale randomised controlled t...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1007/s10557-018-06846-w

    authors: Chiesa ST,Charakida M

    更新日期:2019-04-01 00:00:00

  • Pharmacogenomics to Revive Drug Development in Cardiovascular Disease.

    abstract::Investment in cardiovascular drug development is on the decline as large cardiovascular outcomes trials require considerable investments in time, efforts and financial resources. Pharmacogenomics has the potential to help revive the cardiovascular drug development pipeline by providing new and better drug targets at a...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1007/s10557-015-6637-y

    authors: Dubé MP,de Denus S,Tardif JC

    更新日期:2016-02-01 00:00:00

  • Mitochondrial-Shaping Proteins in Cardiac Health and Disease - the Long and the Short of It!

    abstract::Mitochondrial health is critically dependent on the ability of mitochondria to undergo changes in mitochondrial morphology, a process which is regulated by mitochondrial shaping proteins. Mitochondria undergo fission to generate fragmented discrete organelles, a process which is mediated by the mitochondrial fission p...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1007/s10557-016-6710-1

    authors: Ong SB,Kalkhoran SB,Hernández-Reséndiz S,Samangouei P,Ong SG,Hausenloy DJ

    更新日期:2017-02-01 00:00:00

  • Genetic defects of cardiac ion channels. The hidden substrate for torsades de pointes.

    abstract::The novel insights provided by the molecular genetic applied to the study of cardiac arrhythmias have just started to scratch the surface of the complex relationships between the genetic abnormalities of ion channel structure and the susceptibility to life threatening ventricular arrhythmias. These crucial pieces of i...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1023/a:1015793113771

    authors: Priori SG,Napolitano C

    更新日期:2002-03-01 00:00:00

  • Comparative study of time-course of hemodynamic effect of isosorbide dinitrate spray and sublingual tablets in patients with pulmonary congestion.

    abstract::We compared the time-course of the hemodynamic effect of isosorbide dinitrate (ISDN), 5 mg, in the form of sublingual tablet and oral spray, in 15 patients with isolated chronic pulmonary congestion (pulmonary arterial end-diastolic pressure of 15 mmHg or more in the presence of normal or only slightly reduced cardiac...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/BF00051192

    authors: Marchionni N,De Bari M,Ferrucci L,Moschi G,Schneeweiss A

    更新日期:1988-11-01 00:00:00

  • Functional antagonism of different angiotensin II type I receptor blockers in human arteries.

    abstract:OBJECTIVES:To evaluate and compare the functional type and the degree of antagonism of the selective angiotensin II type 1 receptor blockers (ARB) losartan, EXP 3174 (the active metabolite of losartan), valsartan and candesartan in human internal mammary arteries. METHODS:Human internal mammary arteries were obtained ...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1023/a:1021729909456

    authors: Wagenaar LJ,Voors AA,Buikema H,van Buiten A,Lübeck RH,Boonstra PW,van Veldhuisen DJ,van Gilst WH

    更新日期:2002-07-01 00:00:00

  • Therapeutic advances in heart failure.

    abstract::Annual mortality from congestive heart failure ranges from 15% to 60%, depending on the severity of the left ventricular damage and underlying disease. Most controlled trials have been too small to detect any beneficial effect on survival from the newer vasodilator and inotropic drugs. However, the results of two rece...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:

    authors: Meinertz T,Drexler H,Just H

    更新日期:1988-11-01 00:00:00

  • Recombinant human interleukin-1 receptor antagonist provides cardioprotection during myocardial ischemia reperfusion in the mouse.

    abstract:PURPOSE:Acute myocardial infarction (AMI) drives an intense inflammatory response that contributes to infarct healing and cardiac remodeling. Recently, different studies have identified a role of interleukin-1 (IL-1) in the development of adverse cardiac remodeling. However, in animal models of AMI IL-1 has been shown ...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-012-6389-x

    authors: Toldo S,Schatz AM,Mezzaroma E,Chawla R,Stallard TW,Stallard WC,Jahangiri A,Van Tassell BW,Abbate A

    更新日期:2012-06-01 00:00:00

  • Effects of transdermal nicotine patches on ambulatory ECG monitoring findings: a double-blind study in healthy smokers.

    abstract::The cardiovascular effects and safety of transdermal nicotine patches were assessed in 50 healthy smokers using repeated 48 hour ambulatory electrocardiographic monitoring as a part of a smoking cessation program. Following baseline measurements, subjects were randomized to active (n = 25) or placebo (n = 25) treatmen...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF00823596

    authors: Khoury Z,Comans P,Keren A,Lerer T,Gavish A,Tzivoni D

    更新日期:1996-05-01 00:00:00

  • Should calcium antagonists be first-line agents in the treatment of cardiovascular disease? The public health perspective.

    abstract::The calcium antagonist (CA) controversy has been fueled in part by disagreements among scientists and clinicians over the scientific documentation required for drugs used to treat lifelong conditions. From a public health perspective, there are three unanswered questions: (1) Does long-term use of CAs convey health be...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/BF00051111

    authors: Furberg CD,Psaty BM

    更新日期:1996-09-01 00:00:00

  • Correction to: Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)?

    abstract::The original version of this article unfortunately contained a mistake. There was a typo in the second sentence of the paragraph under the section Was the Dose of Drugs Fair?; "320 mg twice a day" should read "160mg twice a day". The corrected paragraph is shown below. ...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,已发布勘误

    doi:10.1007/s10557-018-6834-6

    authors: Ahn R,Prasad V

    更新日期:2018-12-01 00:00:00

  • Calcium channel antagonists: Part VI: Clinical pharmacokinetics of first and second-generation agents.

    abstract::A survey of the pharmacokinetic properties of the three prototypical calcium antagonist agents shows that they have in common a very high rate of hepatic first-pass metabolism with, in the case of verapamil and diltiazem, the formation of an active metabolite that affects the dose during chronic therapy. Therefore, th...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1007/BF01865507

    authors: Opie LH

    更新日期:1989-08-01 00:00:00

  • Effect of trimetazidine on late potentials after acute myocardial infarction.

    abstract::The purpose of this study was to evaluate the effect of trimetazidine on late potentials in patients with acute myocardial infarction. A total of 60 patients (52 males, mean age 55 +/- 2 years, and 8 females, mean age 54 +/- 1.8 years) with the diagnosis of acute myocardial infarction were included in this study. The ...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1023/a:1007740311072

    authors: Ozdemir R,Tuncer C,Aladag M,Güven A,Sezgin AT,Pekdemir H,Korkmaz ME,Müderrisoglu H

    更新日期:1999-04-01 00:00:00

  • Calcium channel blockers reduce blood pressure in part by inhibiting vascular smooth muscle carbonic anhydrase I.

    abstract::Calcium channel blockers are a group of drugs used for the treatment of hypertension. Carbonic anhydrase (CA) I detected in vascular smooth muscle and in other cells in the organism has a major role in the acid-base balance and in vascular processes. Our previous work has proven that verapamil inhibits CA activity by ...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1023/a:1007893207279

    authors: Puscas L,Gilau L,Coltau M,Pasca R,Domuta G,Baican M,Hecht A

    更新日期:2000-10-01 00:00:00

  • LOX-1 and obesity.

    abstract::Obesity is one of the most common lifestyle-related diseases. Being closely associated with insulin resistance, hypertension and dyslipidemia, it is also a component of metabolic syndrome and is involved in the development of atherosclerosis and cardiovascular and renal ailments. Obesity is also accompanied with a sta...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1007/s10557-011-6335-3

    authors: Yan M,Mehta JL,Hu C

    更新日期:2011-10-01 00:00:00

  • The effects of oral pretreatment with zofenopril, an angiotensin-converting enzyme inhibitor, on early reperfusion and subsequent electrophysiologic stability in the pig.

    abstract::The effects of oral zofenopril pretreatment were investigated in a chronic closed-chest pig model of ischemia and reperfusion. Pigs (25-35 kg) were pretreated orally with zofenopril (15 mg/day) on the 2 days prior to ischemia, which was evoked by the inflation of a catheter balloon in the left anterior descending coro...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/BF01856557

    authors: Tio RA,de Langen CD,de Graeff PA,van Gilst WH,Bel KJ,Wolters KG,Mook PH,van Wijngaarden J,Wesseling H

    更新日期:1990-06-01 00:00:00

  • Influence of the new class I antiarrhythmic agent diprafenone on the end-systolic pressure-volume relationship (conductance technique).

    abstract::To evaluate cordiodepressive risks of antiarrhythmic treatment with diprafenone, we monitored, in addition to conventional hemodynamic parameters, end-systolic pressure-volume relations to assess potential negative inotropic effects. Thirteen patients underwent hemodynamic analysis with and without the influence of di...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/BF01883858

    authors: Thormann J,Kramer W,Kremer P,Schlepper M

    更新日期:1989-04-01 00:00:00

  • Recovery of left ventricular function following early reperfusion in acute myocardial infarction: a potential role for the calcium antagonist nisoldipine.

    abstract::The purpose of the present study was to test whether the administration of a vascular-selective organic calcium antagonist (nisoldipine) at the onset of early mechanical reperfusion (by coronary angioplasty) in acute myocardial infarction could prevent or attenuate postischemic stunning and enhance the recovery of lef...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1023/a:1007713118941

    authors: Sheiban I,Tonni S,Chizzoni A,Marini A,Trevi G

    更新日期:1997-03-01 00:00:00

  • Hemodynamic and antiischemic effects of intravenous elgodipine, a new dihydropyridine calcium channel blocker, in patients with chronic stable angina.

    abstract::Elgodipine is a new second-generation dihydropyridine calcium antagonist. Its hemodynamic and antiischemic properties were evaluated in a single-blind, placebo-controlled trial in 22 males with chronic stable angina. Coronary artery disease was angiographically confirmed. Measurements were performed with a Swan-Ganz t...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 临床试验,杂志文章

    doi:10.1007/BF00878092

    authors: Kuhn A,Carlsson J,Miketic S,Tebbe U

    更新日期:1995-08-01 00:00:00

  • Cholesterol confusion in primary prevention of coronary artery disease.

    abstract::Despite the impressive relation between an increased blood cholesterol and increased mortality from coronary artery disease and despite the persuasive results of cholesterol-lowering trials in secondary prevention, there are increasing reservations about the wisdom of lowering moderately raised blood cholesterol level...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 社论

    doi:10.1007/BF00878930

    authors: Opie LH

    更新日期:1993-11-01 00:00:00

  • Effect of an educational program (PEGASE) on cardiovascular risk in hypercholesterolaemic patients.

    abstract:BACKGROUND:Many studies have demonstrated a gap between guidelines for the prevention of cardiovascular disease (CVD) and their implementation in clinical practice. AIM:The PEGASE education program has been devised with an aim to improve the management of patients at high risk of CVD. METHODS:In a multicentre study c...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s10557-008-6137-4

    authors: Bruckert E,Giral P,Paillard F,Ferrières J,Schlienger JL,Renucci JF,Abdennbi K,Durack I,Chadarevian R,PEGASE group.

    更新日期:2008-12-01 00:00:00

  • Effect of propranolol on ventricular repolarization and refractoriness: role of beta-blockade versus direct membrane effects.

    abstract::The purpose of this study was to define the role of beta-adrenergic blockade and direct membrane effects in the ability of dl-propranolol to alter ventricular repolarization and refractoriness in the intact heart. The effective refractory period (ERP) and the local Q-T interval were measured at an epicardial site in t...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/BF02125746

    authors: Euler DE,Scanlon PJ

    更新日期:1988-03-01 00:00:00